Fig. 2: HDAC activity assays confirm the inhibitory effects of the reduced forms of (R)-lipoic acid, (R/S)-lipoic acid, and (R/S)-lipoamide. | Nature Communications

Fig. 2: HDAC activity assays confirm the inhibitory effects of the reduced forms of (R)-lipoic acid, (R/S)-lipoic acid, and (R/S)-lipoamide.

From: Chemoproteomic target deconvolution reveals Histone Deacetylases as targets of (R)-lipoic acid

Fig. 2: HDAC activity assays confirm the inhibitory effects of the reduced forms of (R)-lipoic acid, (R/S)-lipoic acid, and (R/S)-lipoamide.The alternative text for this image may have been generated using AI.

a Influence of the reducing agent TCEP (0.5 M) on (R/S)-LA mediated HDAC enzymatic activity via reduction and ring opening of the drug (for (R/S)-LM see Supplementary Fig. 2b) (n = 3 technical replicates, data are represented as mean value ± SEM). b HDAC inhibitory effect of the (R)-enantiomer of lipoic acid compared to the (S)-enantiomer (n = 3 technical replicates, data are represented as mean value ± SEM). c Exemplary dose-response profiles of all compounds tested for HDAC1 inhibition in the presence of 0.5 M TCEP ((R/S)-LA red = (R/S)-dihydrolipoic acid). n = 3 technical replicates. d Summary of EC50 values derived from dose-dependent HDAC inhibition curves. Source data are provided as a Source Data file.

Back to article page